Amarantus Bioscience Holdings Inc

OTC:AMBS

Amarantus BioScience Holdings, Inc. is a biopharmaceutical company. The company is headquartered in San Francisco, California. The company went IPO on 2008-09-29. The firm has approximately three operating divisions: the diagnostics division, the therapeutics division and the drug discovery division. The company owns licenses to various product candidates in the therapeutic and diagnostic sectors of the life sciences industry. The company is developing diagnostic product candidates in the field of neurology, and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology and regenerative medicine. The Company, through its subsidiary, Cutanogen Corporation, is developing a regenerative medicine cell therapy-based autologous skin replacement product, Engineered Skin substitute, which is in mid-stage clinical development, for the treatment of life-threatening severe burns. The company is also developing a mid-stage clinical-stage pharmaceutical drug candidate, Eltoprazine, a small molecule 5HT1a/1b partial agonist for the treatment of symptomatic neurological disorders.